ArticleThe American surgeon2016
Improved Postoperative Survival for Intraductal-Growth Subtype of Intrahepatic Cholangiocarcinoma.
Article in The American surgeon, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Efficacy of transarterial chemoembolization combined with PD-1 versus PD-L1 inhibitors in mass-forming intrahepatic cholangiocarcinoma: a multicenter retrospective study.Translational cancer research · 2026Article
- Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review.Surgery today · 2025Review
- Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line, ICC-X2.World journal of oncology · 2024Article
- Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line, ICC-X3.Human cell · 2023Article
- Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.Journal of clinical and translational hepatology · 2022Review
- Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: A case series of 68 patients.World journal of gastrointestinal surgery · 2022Article
- A rare case of intrahepatic cholangiocarcinoma with tumor thrombus in the bile duct.Clinical journal of gastroenterology · 2021Article
- Long noncoding RNA LINC01296 promotes tumor growth and progression by sponging miR-5095 in human cholangiocarcinoma.International journal of oncology · 2018Article
- Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Intrahepatic cholangiocarcinoma (ICC) is classified according to the following subtypes: massforming (MF), periductal infiltrating (PI), and intraductal growth (IG). The aim of this study is to measure the association between ICC subtypes and patient survival after surgical resection. Data were abstracted on all patients treated with definitive resections of ICC at a single institution between 2000 and 2011 with at least three years follow-up. Survival estimates were quantified using Kaplan-Meier curves and compared using the log-rank test. There were 37 patients with ICC treated with definitive partial hepatectomies with a median survival of 33.5 months. Tumor stage (P < 0.0001), satellitosis (P < 0.001), lymphovascular space invasion (P = 0.003), and macroscopic subtype (P = 0.003) were predictive of postoperative survival. Disease-free survivals for MF, PI, and IG subtypes, respectively, were 30 per cent, 0 per cent, and 57 per cent (P = 0.017). Overall survivals among ICC macroscopic subtypes were as follows: MF 37 per cent, PI 0 per cent, and IG 71 per cent (P = 0.003). Although limited by the small sample size of this rare cancer, this study demonstrates significant differences among macroscopic subtypes of ICC in both disease-free survivals and overall survivals after definitive partial hepatectomy.
Indexed as
Identifiers
28206944PMC5748294W2982026442What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.